[go: up one dir, main page]

Shepley-McTaggart, 2023 - Google Patents

Investigating Host Regulation of the Filovirus Lifecycle

Shepley-McTaggart, 2023

View PDF
Document ID
14689752342950367659
Author
Shepley-McTaggart A
Publication year

External Links

Snippet

Abstract Filoviruses Ebola (EBOV) and Marburg (MARV) are emerging pathogens capable of causing explosive outbreaks with high mortality rates. Host proteins play critical roles in regulating (positively or negatively) EBOV and MARV entry and exit, and their identification …
Continue reading at repository.upenn.edu (PDF) (other versions)

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse Transcribing RNA Viruses
    • C12N2740/00011—Reverse Transcribing RNA Viruses
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay
    • G01N33/569—Immunoassay; Biospecific binding assay for micro-organisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof

Similar Documents

Publication Publication Date Title
Bohan et al. Phosphatidylserine receptors enhance SARS-CoV-2 infection
US11802273B2 (en) Mutations that confer genetic stability to additional genes in influenza viruses
Le Tortorec et al. Antagonism to and intracellular sequestration of human tetherin by the human immunodeficiency virus type 2 envelope glycoprotein
US11241492B2 (en) Mutations that confer genetic stability to genes in influenza viruses
Scaturro et al. Dengue virus non-structural protein 1 modulates infectious particle production via interaction with the structural proteins
Jaume et al. Anti-severe acute respiratory syndrome coronavirus spike antibodies trigger infection of human immune cells via a pH-and cysteine protease-independent FcγR pathway
Saeed et al. Cellular entry of ebola virus involves uptake by a macropinocytosis-like mechanism and subsequent trafficking through early and late endosomes
Qi et al. Rab11-FIP1C and Rab14 direct plasma membrane sorting and particle incorporation of the HIV-1 envelope glycoprotein complex
Jalloh et al. CD169-mediated restrictive SARS-CoV-2 infection of macrophages induces pro-inflammatory responses
Dubé et al. Rubella virus: first calcium-requiring viral fusion protein
Kudelko et al. Class II ADP-ribosylation factors are required for efficient secretion of dengue viruses
Russell et al. Conserved glycine residues in the fusion peptide of the paramyxovirus fusion protein regulate activation of the native state
Yang et al. Annexin 2 is a host protein binding to classical swine fever virus E2 glycoprotein and promoting viral growth in PK-15 cells
Khan et al. TMPRSS2 promotes SARS-CoV-2 evasion from NCOA7-mediated restriction
Zhang et al. Fusogenic structural changes in arenavirus glycoproteins are associated with viroporin activity
US20230331815A1 (en) Methods and compositions for treating viral infection
Shepley-McTaggart Investigating Host Regulation of the Filovirus Lifecycle
Stevens et al. Alpha-1-antitrypsin and its variant-dependent role in COVID-19 pathogenesis
Nguyen Functional characterization of the nuclear localization signals of influenza A virus nucleoprotein and the nucleolar protein 14
Westerbeck et al. The Infectious Bronchitis Virus Coronavirus Envelope Protein Alters Golgi pH to Protect Spike Protein and Promote Release of Infectious Virus
Qu SARS-CoV-2: Neutralizing Antibody Responses and Modulation by Host Restriction Factors
Gonçalves Carneiro Molecular mechanisms of measles virus entry and exit
Tang Insights in Coronavirus Entry Function and Their Applications in the Prevention of Infection
Biwas A genetic analysis of NPC1 receptor activity in Ebola virus infection
Miao Cell-to-cell infection, cell-cell fusion and production of ebolavirus: mechanisms of action and cellular modulators